Treatment News : Study: ARV Treatment Reduces HIV Transmission 96 Percent

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » May 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


May 12, 2011

Study: ARV Treatment Reduces HIV Transmission 96 Percent

A study funded by the National Institutes of Health (NIH) has confirmed that treating HIV-positive people with antiretroviral (ARV) drugs reduces the risk of transmitting the virus to HIV-negative sexual partners by 96 percent—at least among heterosexual couples—according to an announcement by the NIH.

The study, called HPTN 052, enrolled nearly 1,800 HIV-serodiscordant couples, in which one parter is HIV positive and the other is HIV negative. All but one of the study couples were heterosexual male and female couples. Based on the study design, all of the HIV-positive participants had to have a CD4 count between 350 and 550 upon entering the study. After the study began, the HIV-positive participants were randomized to either start ARV therapy right away (the early treatment group) or to wait until their CD4s dropped below 250 or they developed an AIDS-related illness (the delayed treatment group). All of the people in the study, which took place in multiple sites around the globe, received HIV care, access to condoms and thorough prevention counseling.

HPTN 052 was originally scheduled to continue until 2015. An early look at the data by the data safety monitoring board (DSMB), however, found that those in the early treatment group were much less likely than those in the delayed treatment group to transmit HIV to their partners and, thus, it would be unnecessary to continue to the trial.

In the data that the DSMB reviewed, there were 39 new HIV-infections among the HIV-negative participants—28 of which could be traced directly between the HIV-positive study participants and their HIV-negative partner. Of the 28 new infections, 27 occurred in the delayed treatment group, compared with just one in the early treatment group—a 96 percent reduction in new infections.

It should be noted, however, that the results can’t necessarily be extrapolated to couples where both partners are male. Nevertheless, the results do add to a recent string of prevention success stories, and advocates are expressing enthusiasm.

“These results allow us to imagine a world in which men and women seek HIV testing with the knowledge and confidence that they will receive a range of highly effective options for staying healthy and protecting themselves and their partners—whatever the test result,“ said Mitchell Warren, executive director of the AIDS Vaccine Advocacy Coalition.

Investigators from the recently completed iPrEx study—which found that ARV treatment in HIV-negative people (PrEP) could protect them from infection—also lauded the results.

“iPrEx congratulates the participants and researchers involved in HPTN 052,” they said. “This important study proves that providing early antiretroviral treatment significantly improves health among people living with HIV and dramatically reduces new HIV infections in their partners.”

Despite the significant advances in HIV prevention options of late—ranging from PrEP to vaginal gels to treatment of HIV-positive people as prevention—scientists and advocates are concerned that more funding needs to become available in order to realize the potential of these options. This will be particularly true in resource-poor countries where the majority of people with HIV still don’t have access to ARVs for their own health, and where those who do often have to wait to access treatment until their CD4s drop below 200.

“Never before have so many effective HIV prevention tools and strategies been available,” the iPrEx researchers stated. “The challenge before funders and policy makers now is to increase investments to make new HIV treatment and prevention tools available to everyone who needs them.”

Warren agreed. “We need to start critical discussions and come to quick decisions about where and how to deploy treatment as prevention in the short-term,” he said. “Government and international normative agencies now have a critical mass of data to publish guidelines for appropriate implementation of treatment as prevention in concert with other prevention methods.”

Search: HPTN 052, treatment as prevention, clinical trial, heterosexual transmission, NIH, iPrEx, Mitchell Warren, AIDS Vaccine Advocacy Coalition, AVAC, PrEP, vaginal gel, funding

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (3 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.